Singapore markets open in 8 hours 57 minutes

SCYNEXIS, Inc. (SCYX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.4700-0.0300 (-2.00%)
As of 12:02PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.5000
Open1.5800
Bid1.4500 x 100
Ask1.4700 x 100
Day's range1.4200 - 1.4899
52-week range1.3500 - 3.8700
Volume56,095
Avg. volume201,958
Market cap55.498M
Beta (5Y monthly)1.57
PE ratio (TTM)1.06
EPS (TTM)1.3900
Earnings date08 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.88
  • GlobeNewswire

    SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address sy

  • GlobeNewswire

    SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

    SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo

  • GlobeNewswire

    SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

    JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed